|
VisionCare Ophthalmic Technologies, Inc. |
|
|
14395 Saratoga Ave, Ste 150
Saratoga, CA 95070 USA
phone:408.872.9393
fax:408.872.9395
|
|
| Symbol |
Private |
| Founded |
2001 |
| Employees |
|
|
|
| www.visioncareinc.net
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Implantable ophthalmic devices for untreatable retinal disorders |
|
| Management |
| Allen W. Hill, President and CEO; Joaquin V. Wolff, Chief Commercial Officer; Richard P. Powers, Executive Vice President; Eli Aharoni, Vice President, Research & Development and General Manager; Boris Aradovsky, Vice President, Quality Assurance and Regulatory Affairs; Yona Katz, Vice President, Manufacturing; Chet Kuma, Vice President, Business and Market Development; Doron Raz, Vice President, Finance and Administration |
| |
|
|
| |
|
| Keywords |
| implantable, ophthalmic, retinal disorder, prosthetic, age-related macular degeneration, advamed |
|
|
|
| Description |
|
VisionCare Ophthalmic Technologies researches, develops, manufactures, and markets proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. VisionCare’s lead product, the Implantable Miniature Telescope, is the first FDA-approved implantable medical device demonstrated to improve vision in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD), end-Stage AMD, which is the leading cause of blindness in older Americans. VisionCare’s telescope implant is surgically placed inside the capsular bag after removal of the lens of the eye, which enables the patient to see using natural eye movements; magnification enlarges images before the eye, allowing them to be projected onto healthy perimacular areas of the retina, reducing the patient’s “blind spot” and allowing the patient to distinguish previously unrecognizable images. As of September 2011, Medicare has established reimbursement for the Implantable Miniature Telescope. The goal of this later-stage medical device company is to develop further technological advances to help the vision-impaired. |
|
| Market / Customers |
AMD, affecting individuals over the age of 50, is the leading cause of permanent visual impairment and blindness in the US. Although individuals diagnosed with early AMD do not have significant vision loss, those with advanced AMD can have significant permanent vision loss that affects their ability to perform everyday activities, such as going shopping, recognizing people, and watching television. The National Eye Institute reports that over 1.6 million individuals have advanced AMD in the US, primarily affecting those over the age of 65. Approximately half of these individuals are affected in both eyes, which can severely impair the ability to function in vision-dependent activities. VisionCare is in late-stage clinical development of their lead product to help improve vision and quality of life for those affected by advanced AMD in both eyes.
|
|
| Funding |
| VisionCare is a venture capital backed company. Major investors include Onset Ventures, Three Arch Partners, Pitango Venture Capital, and Infinity Venture Capital. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members